Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vermillion has entered into an exclusive license agreement with Stanford University to develop and commercialize a novel biomarker panel used to assess the risk of peripheral artery disease or PAD.
Subscribe to our email newsletter
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test, which utilizes the multi-marker panel to stratify an individual’s risk for developing the disease.
In collaboration with Stanford, Vermillion has completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD. Additionally, Vermillion is establishing a clinical steering committee to guide and provide advice on a clinical trial to support registration of the PAD test with the FDA.